SEHK:1548

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life sciences research products and services in North America, Europe, China, Japan, the other Asia Pacific regions, and internationally.


Snowflake Analysis

Adequate balance sheet with limited growth.


Similar Companies

Share Price & News

How has Genscript Biotech's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1548's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.5%

1548

-2.8%

HK Life Sciences

4.1%

HK Market


1 Year Return

-17.3%

1548

61.4%

HK Life Sciences

-4.7%

HK Market

Return vs Industry: 1548 underperformed the Hong Kong Life Sciences industry which returned 61.6% over the past year.

Return vs Market: 1548 underperformed the Hong Kong Market which returned -4.9% over the past year.


Shareholder returns

1548IndustryMarket
7 Day1.5%-2.8%4.1%
30 Day-15.2%4.2%5.3%
90 Day33.2%29.6%13.5%
1 Year-17.3%-17.3%61.4%61.4%-1.2%-4.7%
3 Year259.5%259.5%307.8%307.7%7.7%-3.5%
5 Yearn/a103.5%98.0%7.2%-10.1%

Price Volatility Vs. Market

How volatile is Genscript Biotech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Genscript Biotech undervalued compared to its fair value and its price relative to the market?

10.22x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 1548's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 1548's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 1548 is unprofitable, so we can't compare its PE Ratio to the Life Sciences industry average.

PE vs Market: 1548 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1548's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1548 is overvalued based on its PB Ratio (10.2x) compared to the HK Life Sciences industry average (7.1x).


Next Steps

Future Growth

How is Genscript Biotech forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

13.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1548 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 1548 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 1548 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 1548's revenue (22.7% per year) is forecast to grow faster than the Hong Kong market (11% per year).

High Growth Revenue: 1548's revenue (22.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 1548 is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Genscript Biotech performed over the past 5 years?

-39.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1548 is currently unprofitable.

Growing Profit Margin: 1548 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 1548 is unprofitable, and losses have increased over the past 5 years at a rate of -39% per year.

Accelerating Growth: Unable to compare 1548's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1548 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (62.3%).


Return on Equity

High ROE: 1548 has a negative Return on Equity (-31.57%), as it is currently unprofitable.


Next Steps

Financial Health

How is Genscript Biotech's financial position?


Financial Position Analysis

Short Term Liabilities: 1548's short term assets ($554.0M) exceed its short term liabilities ($224.5M).

Long Term Liabilities: 1548's short term assets ($554.0M) exceed its long term liabilities ($292.6M).


Debt to Equity History and Analysis

Debt Level: 1548's debt to equity ratio (5%) is considered satisfactory.

Reducing Debt: 1548's debt to equity ratio has reduced from 13.1% to 5% over the past 5 years.

Debt Coverage: 1548's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if 1548's interest payments on its debt are well covered by EBIT.


Balance Sheet


Next Steps

Dividend

What is Genscript Biotech current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 1548's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 1548's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1548's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1548's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 1548 is not paying a notable dividend for the Hong Kong market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1548's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.7yrs

Average management tenure


CEO

Frank Zhang (55yo)

no data

Tenure

US$488,000

Compensation

Dr. Fangliang Zhang, also known as Frank, Ph.D. serves as Chairman of the Board of Legend Biotech Corporation since May 2015. Dr. Zhang serves as the Executive Chairman of Genscript Biotech Corporation. Dr ...


CEO Compensation Analysis

Compensation vs Market: Frank's total compensation ($USD488.00K) is about average for companies of similar size in the Hong Kong market ($USD478.38K).

Compensation vs Earnings: Frank's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Fangliang Zhang
Co-Founderno dataUS$488.00kno data
Ye Wang
Co-Founder5.17yrsUS$601.00k0.0014% $420.9k
Jiange Meng
Secretary of the Board & Executive Director4.92yrsUS$221.00kno data
Aaron Qian
Financial Directorno datano datano data
Chuan-Chu Chou
Head of Discovery and Preclinical Services7.75yrsno datano data
Chifa Zhang
Department Head of Industry Synthetic Biology Product Segment6.5yrsno datano data
Brian Hosung Min
CEO of Biologics Businessno datano datano data
Wai Ling Wong
Company Secretary4.92yrsno datano data
Yuan Xu
Chief Executive Officer of Legendno datano datano data
Shiniu Wei
Vice President of Strategy & Investor Relationsno datano datano data

5.7yrs

Average Tenure

52yo

Average Age

Experienced Management: 1548's management team is seasoned and experienced (5.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Fangliang Zhang
Co-Founderno dataUS$488.00kno data
Ye Wang
Co-Founder5.17yrsUS$601.00k0.0014% $420.9k
Jiange Meng
Secretary of the Board & Executive Director4.92yrsUS$221.00kno data
Yuexin Pan
Non-Executive Director4.92yrsUS$137.00kno data
Hong Xin Guo
Independent Non-Executive Director4.92yrsUS$137.00kno data
Jon Stonehouse
Member of Advisory Boardno datano datano data
Zumian Dai
Independent Non-Executive Director4.92yrsUS$137.00kno data
Luquan Wang
Non-Executive Director5.17yrsno datano data
Jiuan Pan
Independent Non-Executive Director1.67yrsUS$31.00kno data
Jiafen Wang
Non-Executive Director1.67yrsUS$31.00kno data

4.9yrs

Average Tenure

53.5yo

Average Age

Experienced Board: 1548's board of directors are considered experienced (4.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 1548 insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.1%.


Top Shareholders

Company Information

Genscript Biotech Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Genscript Biotech Corporation
  • Ticker: 1548
  • Exchange: SEHK
  • Founded: 2002
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$30.948b
  • Shares outstanding: 1.92b
  • Website: https://www.genscript.com

Number of Employees


Location

  • Genscript Biotech Corporation
  • Jiangning Science Park
  • No. 28, Yongxi Road
  • Nanjing
  • Jiangsu Province
  • 211122
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
1548SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDDec 2015
G51DB (Deutsche Boerse AG)YesOrdinary SharesDEEURDec 2015
GNNS.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDDec 2015
1548SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect)YesOrdinary SharesHKHKDDec 2015
1548SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect)YesOrdinary SharesHKHKDDec 2015

Biography

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life sciences research products and services in North America, Europe, China, Japan, the other Asia Pacific regions, and internationally. It operates in four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein production, peptide synthesis, and antibody development for use in basic biology studies, disease and pharmaceutical research, drug discovery, agriculture, environmental studies, and food industry; life sciences research catalogue products, such as pre-packaged, ready-to-use, and off-the-shelf products; and contractual research services, including protein engineering. The Biologics Development Services segment provides various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for antibody therapeutic antibodies and gene/cell therapy products. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes. The Cell Therapy segment discovers and develops therapies for the treatment of liquid tumors. The company was founded in 2002 and is headquartered in Nanjing, China. Genscript Biotech Corporation is a subsidiary of GenScript Corporation. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/04 12:38
End of Day Share Price2020/07/03 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.